Tonix licenses exclusive worldwide rights to TNX-4900 for neuropathic pain from Rutgers University

Tonix Pharmaceuticals Holding Corp.

Licensed exclusive worldwide rights to TNX-4900 (S1R antagonist) from Rutgers University for chronic neuropathic pain.
TNX-4900: Ki=7.5 nM, >100-fold selectivity over Sigma-2, oral bioavailability ~28%.
Preclinical efficacy in diabetic and chemotherapy-induced neuropathic pain models without tolerance or motor impairment.
Company plans IND-enabling studies; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.